After a trial involving nearly 18000 participants, the US FDA approves Wegovy, one of the famed GLP-1 anti-obesity medications, for reducing the chance of cardiovascular death, heart attack or stroke in adults with cardiovascular disease who live with obesity or overweight. That’s currently most, about 70%, of American adults, although there are a few contraindications.

Treating obesity can save lives.